S&P 500
5.070,55 +59,95 (+1,20%) Nasdaq
15.696,64 +245,33 (+1,59%) NIKKEI 225
38.460,08 +907,92 (+2,42%) Dólar/Euro
1,0696 -0,0008 (-0,07%) Petróleo Brent
88,71 +0,29 (+0,33%) Bitcoin EUR
62.430,35 +373,18 (+0,60%)
Esperion Therapeutics, Inc. (ESPR)
Después del cierre:
Esperion Therapeutics, Inc.
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 240
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sheldon L. Koenig | President, CEO & Director | 1,28M | N/A | 1966 |
| Dr. JoAnne Micale Foody FACC, M.D. | Chief Medical Officer | 856,87k | N/A | 1965 |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 718,86k | N/A | 1972 |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | N/A | N/A | 1986 |
| Mr. Glenn P. Brame | Chief Technical Operations Officer | N/A | N/A | 1958 |
| Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary | 550,35k | N/A | 1982 |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | N/A | N/A | N/A |
| Ms. Betty Jean Swartz | Chief Business Officer | N/A | N/A | N/A |
Descripción
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Gobierno corporativo
El ISS Governance QualityScore de Esperion Therapeutics, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 4; Tablero: 5; Derechos de los accionistas: 8; Compensación: 9.
